ErbB3

ErbB3

ErbB3 Overview

Molecule Name
Receptor tyrosine-protein kinase erbB-3
Synonyms
ERBB3,HER3,LCCS2,MDA-BF-1,MGC88033,c-erbB3,erbB3-S,p180-ErbB3,p45-sErbB3,p85-sErbB3
Drug Development Progress
Drugs in Clinical Trials31
Approved Drugs2
Highest Development StageApproved
Target Synonym
EC:2.7.10.1,FERLK,EC 2.7.10,Proto-oncogene-like protein c-ErbB-3,HER3,ERBB3,Erb-B2 Receptor Tyrosine Kinase 3,V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 3,Tyrosine Kinase-Type Cell Surface Receptor HER3,Human Epidermal Growth Factor Receptor 3,Lethal Congenital Contracture Syndrome 2,Receptor Tyrosine-Protein Kinase ErbB-3,EC 2.7.10.1,P180-ErbB3,P45-SErbB3,P85-SErbB3,MDA-BF-1,C-ErbB-3,C-ErbB3,ErbB3-S,ErbB-3,LCCS2,Receptor, ErbB-3
Background
ErbB3,also known as Her3 (human epidermal growth factor receptor 3), is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases. This membrane-bound glycoprotein has a neuregulin binding domain but has not an active kinase domain. It therefore can bind the ligand but cannot mediate the intracellular signal transduction through protein phosphorylation. However, it does form heterodimers with ErbB2 or other EGFR members responsible for tyrosine phosphorylation to give a receptor complex and initiate the related pathway, which lead to cell proliferation or differentiation. Overexpression of this protein has been reported in numerous cancers, including prostate, bladder, and breast tumors. This protein has different isoforms derived from alternative splicing variants, and among which, the secreted isoform lacking the intermembrane region modulates the activity of membrane-bound form.

ErbB3 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
IzalontamabSI-B001; SI-1X6.4Phase 3 ClinicalSichuan Baili Pharmaceutical Co Ltd
Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
JSKN-016JSKN-016; JSKN016Phase 3 ClinicalJiangsu Alphamab Biopharmaceuticals Co Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms
Details
YL-202YL-202; BNT326Phase 3 ClinicalMediLink Therapeutics Co Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms
Details
SHR-A2009SHR-A2009Phase 3 ClinicalSuzhou Suncadia Biopharmaceuticals Co Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Solid tumours; Triple Negative Breast Neoplasms
Details
Patritumab DeruxtecanU3-1402; U3-1402a; MK-1022Phase 3 ClinicalDaiichi Sankyo Co Ltd
Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
NezutatugHMBD-001Phase 2 ClinicalHummingbird Bioscience
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
SapitinibAZD-8931Phase 2 ClinicalAstrazeneca Plc
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Metastatic breast cancer; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms
Details
Allitinib TosylateAST-6; ALS-1306; AST-1306Phase 2 ClinicalShanghai Allist Pharmaceutical Technology Co Ltd
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
HMBD-501ENV-501; HMBD-501; ENV-ONC-501Phase 2 ClinicalHummingbird Bioscience
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Skin Melanoma
Details
JS-212JS212; JS-212Phase 2 ClinicalShanghai Junshi Biosciences Co Ltd
Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Lung Neoplasms; Solid tumours
Details
DB-1418AVZO-1418; DB-1418Phase 2 ClinicalDuality Biologics (Suzhou) Co Ltd
Lung Neoplasms; Neoplasms, Glandular and Epithelial; Solid tumours
Details
89Zr-Patritumab deruxtecanPhase 2 ClinicalDaiichi Sankyo Co Ltd, Daiichi Sankyo Inc, The Netherlands Cancer Institute
Carcinoma, Non-Small-Cell Lung
Details
IBI-133IBI133; IBI-133Phase 2 Clinical
Solid tumours
Details
DB-1310DB-1310Phase 2 ClinicalDuality Biologics (Shanghai) Co Ltd, Duality Biologics (Suzhou) Co Ltd
Neoplasm Metastasis; Solid tumours
Details
SIBP-03SIBP-03Phase 2 ClinicalShanghai Institute of Biological Products Co Ltd
Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
JK-07 (SalubrisBio)JK07; SAL007; SAL-007Phase 2 ClinicalSalubris Biotherapeutics Inc
Heart Failure; Heart Failure, Diastolic; Heart Failure, Systolic; Pulmonary Arterial Hypertension
Details
Recombinat humanized HER3-targeting antibodyPhase 2 ClinicalShanghai Institute of Biological Products Co Ltd
Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
ElgemtumabNOV-6; LJM-716Phase 1 ClinicalMorphosys Ag, Novartis Pharma Ag
Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms
Details
MP-0274DARPin-41; SPA-28; CME-114; CME-115; CME-118; CME-119; MP-0274Phase 1 ClinicalMolecular Partners Ag
Neoplasms
Details
AV-203AV-203; CAN-017Phase 1 ClinicalAveo
Neoplasms; Solid tumours
Details
HDM-2024HDM2024; HDM-2024Phase 1 ClinicalHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Solid tumours
Details
KHN-922KHN-922Phase 1 ClinicalChengdu Kanghong Pharmaceutical Group Co Ltd
Neoplasms; Solid tumours
Details
Sirotinib MaleateXZP-5491Phase 1 ClinicalShandong Xuanzhu Pharmaceutical Technology Co Ltd
Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Stomach Neoplasms
Details
PM1300PM-1300; PM1300Phase 1 Clinical
Neoplasms
Details
AK-138-D-1AK138D1; AK-138-D-1Phase 1 Clinical
Neoplasms; Solid tumours
Details
BL-B16D1BLB16D1; BL-B16D1Phase 1 ClinicalBaili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd
Breast Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
SYS-6023SYS-6023; SYS6023Phase 1 ClinicalJushi Biopharmaceutical Co Ltd
Breast Neoplasms; Metastatic breast cancer; Solid tumours
Details
AMT-562AMT-562Phase 1 ClinicalMultitude Therapeutics Inc
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours; Stomach Neoplasms
Details
SIBP-A13SIBP-A13Phase 1 ClinicalShanghai Institute of Biological Products Co Ltd
Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms; Metastatic breast cancer; Solid tumours
Details
Recombinant human ErbB3 fragment vaccine (Zensun)rhErbB3-fPhase 1 ClinicalZensun (Shanghai) Sci&Tech Co Ltd
Neoplasms
Details
DM-002DM-002; DM002 (Danma)Phase 1 ClinicalDanma (Suzhou) Biomedical Technology Co Ltd
Colorectal Neoplasms; Endometrial Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Osimertinib MesylateAZD-9291; RDL94R2A16; AZD-9291 Mesylate; AZD9291ApprovedAstrazeneca Plc泰瑞沙, TagrissoUnited StatesCarcinoma, Non-Small-Cell LungAstrazeneca Pharmaceutical Co Ltd2015-11-13
Adenocarcinoma; Adenocarcinoma of Lung; Brain metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Meningeal Neoplasms; Multiple Myeloma; Neoplasm, Residual; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
ZenocutuzumabMCLA-128ApprovedMerus NvBizengriUnited StatesPancreatic Neoplasms; Carcinoma, Non-Small-Cell LungMerus Nv2024-12-04
Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours
Details